Stocktoria
CODEXIS, INC. CDXS
CODEXIS, INC. (CDXS) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $70.4M at a -62.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.484 |
| Retained earnings / assets | -4.105 |
| EBIT / assets | -0.282 |
| Equity / liabilities | 0.519 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CDXS | CODEXIS, INC. | 3/9 | -11.56 | — | +18.6% |
| LNZA | LanzaTech Global, Inc. | 2/9 | — | — | +12.6% |
| FF | FutureFuel Corp. | 2/9 | 5.06 | — | -60.7% |
| TANH | TANTECH HOLDINGS LTD | 2/9 | 11.62 | — | -10.7% |
| CNEY | CN ENERGY GROUP. INC. | 4/9 | — | — | -30.2% |
| SAFX | XCF Global, Inc. | 4/9 | -4.58 | 1.6 | — |
| ORGN | Origin Materials, Inc. | 2/9 | -12.77 | — | -39.5% |
About CODEXIS, INC.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
FAQ
Is CDXS financially healthy?
CODEXIS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CDXS pay a dividend?
No, CODEXIS, INC. does not currently pay a dividend.
How profitable is CDXS?
In FY2025, CODEXIS, INC. had a net margin of -62.5% and a return on equity of -87.0%.
What is the analyst price target for CDXS?
The average Wall-Street price target for CODEXIS, INC. is $6.58, about 311.5% above the recent price, from 6 analysts (consensus: buy).
Is CDXS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CODEXIS, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.